Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $101.38, for a total value of $506,900.00. Following the completion of the sale, the chief executive officer owned 2,242,500 shares of the company’s stock, valued at approximately $227,344,650. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

iRadimed Price Performance

Shares of IRMD stock traded down $1.34 during trading on Wednesday, hitting $101.46. 41,499 shares of the stock traded hands, compared to its average volume of 72,331. iRadimed Corporation has a 52-week low of $47.48 and a 52-week high of $107.90. The firm has a market capitalization of $1.30 billion, a P/E ratio of 57.68 and a beta of 1.12. The firm’s fifty day moving average price is $100.44 and its 200-day moving average price is $89.15.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The company had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. This is a boost from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. iRadimed’s dividend payout ratio (DPR) is 45.71%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. grew its position in shares of iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after acquiring an additional 205,783 shares during the last quarter. Goldman Sachs Group Inc. grew its position in iRadimed by 37.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after purchasing an additional 55,426 shares during the last quarter. Informed Momentum Co LLC purchased a new position in iRadimed during the 4th quarter worth $5,361,000. SG Americas Securities LLC increased its stake in iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after purchasing an additional 33,072 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of iRadimed by 473.9% in the fourth quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after buying an additional 29,010 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

IRMD has been the topic of a number of analyst reports. Roth Mkm reaffirmed a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Lake Street Capital reissued a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, iRadimed has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.